Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters
Open Access

The authors reply to: “Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis”

Leigh J. Sowerby and James Fowler
CMAJ March 22, 2021 193 (12) E427; DOI: https://doi.org/10.1503/cmaj.78206
Leigh J. Sowerby
Associate professor, Otolaryngology–Head and Neck Surgery, Western University, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Fowler
Resident, Otolaryngology–Head and Neck Surgery, Western University, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

We thank Dr. Kline and colleagues for their insightful comments regarding the potential risk of hypothalamic–pituitary–adrenal (HPA) axis suppression in certain scenarios with nasal corticosteroids. 1 We agree that physicians should be aware of possible medication interactions, in particular with cytochrome P-450 3A4 (CYP3A4) inhibitors. At the same time, physicians should not shy away from prescribing these medications for most patients with symptomatic nasal complaints because their safety profile is well established.

We would like to comment on the systematic review citing a 4% incidence of biochemical adrenal insufficiency with nasal steroid use.2 Broersen and colleagues reference 8 articles regarding this, but on detailed review of this study, we could identify only 5 with intranasal delivery of corticosteroid, the most recent being from 2004. This also included 2 articles that used corticosteroid drops rather than spray, which is well-known to deliver a higher dose of corticosteroid; this form is not available in Canada owing to the risk of HPA axis suppression.

A much more detailed review of adverse effects with intranasal corticosteroid therapy in adults was published in December 2020.3 Donaldson and colleagues found 28 studies looking specifically at HPA suppression in adults. Of these, 23 reported no evidence of HPA axis suppression, and the 5 studies that did used a corticosteroid delivery method (3 used drops) that was not approved by the US Food and Drug Administration. The same group published a similar systematic review for children4 in which they identified 23 studies that included information on HPA axis suppression. Of these studies, 17 showed no evidence of HPA axis suppression. Five of the 6 that did report some suppression were using intranasal corticosteroid drops.

Given the comorbidity of asthma with chronic rhinosinusitis or allergic rhinitis, it is important to bear in mind that the effect of using both inhaled and intranasal corticosteroid may be additive and heighten the risk for HPA axis suppression. Indeed, 1 of the cases cited by Kline and colleagues was on concurrent inhaled corticosteroid.5 As such, we would suggest selecting a second-generation nasal corticosteroid (e.g., ciclesonide hydrofluoroalkane, mometasone furoate or fluticasone propionate) for patients taking inhaled corticosteroids, and, on occasion, to re-evaluate whether the current intranasal corticosteroid dose and treatment is still required for symptom control.

Footnotes

  • Competing interests: Leigh Sowerby has received personal fees from Mylan, GSK and Sanofi, and grants from GSK, Roche and AstraZeneca, outside of the submitted work. No other competing interests were declared.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Kline GA,
    2. Symonds CJ,
    3. Holmes DT
    . Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis [letter]. CMAJ 2021; 193;E426.
    OpenUrlFREE Full Text
  2. ↵
    1. Broersen LHA,
    2. Pereira AM,
    3. Jørgensen JOL,
    4. et al
    . Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:2171–80.
    OpenUrlPubMed
  3. ↵
    1. Donaldson AM,
    2. Choby G,
    3. Kim DH,
    4. et al
    . Intranasal corticosteroid therapy: systematic review and meta-analysis of reported safety and adverse effects in adults. Otolaryngol Head Neck Surg 2020;163:1097–108.
    OpenUrl
  4. ↵
    1. Donaldson AM,
    2. Choby G,
    3. Kim DH,
    4. et al
    . Intranasal corticosteroid therapy: systematic review and meta-analysis of reported safety and adverse effects in children. Otolaryngol Head Neck Surg 2020;163:1087–96.
    OpenUrl
  5. ↵
    1. Veilleux O,
    2. Lee TC,
    3. McDonald EG
    . Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. CMAJ 2017;189:E1188–91.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 193 (12)
CMAJ
Vol. 193, Issue 12
22 Mar 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The authors reply to: “Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis”
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The authors reply to: “Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis”
Leigh J. Sowerby, James Fowler
CMAJ Mar 2021, 193 (12) E427; DOI: 10.1503/cmaj.78206

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The authors reply to: “Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis”
Leigh J. Sowerby, James Fowler
CMAJ Mar 2021, 193 (12) E427; DOI: 10.1503/cmaj.78206
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The denial of racism is racism itself
  • An expanded role for blood donor emerging pathogens surveillance
  • Beyond wastewater surveillance: refining environmental pathogen detection in the built environment
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire